Activity of EGFR-Directed Therapies
Heterogeneous EGFR-mutated lung adenocarcinomas undergo clonal selection upon treatment of EGFR TKIs. There are sequences of changes in clonal predominance upon treatment exposure/adaptation to 1st & 2nd and subsequently 3rd generation EGFR TKIs.